|
AIMM Therapeutics‚Äô Pre-fusion RSV Antibodies Facilitate Improved Approach …
PharmiWeb.com (press release) AIMM Therapeutics B.V. a leading developer of a new generation of therapeutic antibodies announced today that researchers have used the Company‚Äôs unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved … |
|
AIMM Therapeutics’ Pre-fusion RSV Antibodies Facilitate Improved Approach to …
4-traders (press release) AIMM Therapeutics B.V., a leading developer of a new generation of therapeutic antibodies, announced today that researchers have used the Company’s unique family of antibodies that neutralize respiratory syncytial virus (RSV) to engineer an improved … |
Toronto NewsFIX |
Breast cancer prevented by shark antibodies
Toronto NewsFIX (NewsFix) Scientists are analyzing whether antibodies found only in sharks can be used to help treat breast cancer. Dr Helen Dooley, from the University of Aberdeen’s school of biological sciences, who is leading the study, said: “Our work centres on a … |
The Standard Digital News |
Germ-hunting antibodies may hold key to new HIV treatment
Hamilton Spectator Antibodies are proteins in the blood that grab onto specific germs and mark them for elimination. People infected with HIV naturally make antibodies to fight the AIDS virus, but they are generally ineffective. The two new studies used lab-made versions … HIV-like virus suppressed in monkey experimentR & D Magazine |
|
HIV antibodies ‘have potent impact’
The Standard Digital News The immune system produces precisely targeted antibodies to take out standardmedia.co.ke/?searchtext=HIV&searchbutton=SEARCH’> HIV, but the virus is able to rapidly mutate to evade the immune assault. However, some antibodies have been … |
|
First Proof for Rituximab in IgG4-Related Disease
Medscape SAN DIEGO — Rituximab (Rituxan, Genentech) is a potential treatment option in the multiorgan fibroinflammatory disorder known as immunoglobulin G4-related disease (IgG4), according to researchers reporting first evidence. “New therapeutic strategies … |
OncLiveFDA Approves Frontline Obinutuzumab for CLLOncLiveIn the three-arm study, patients were randomized in a 1:2:2 ratio to receive six cycles every 28 days of chlorambucil (n = 118), chlorambucil plus obinutuzumab (n = 238), or chlorambucil plus rit…
Ars TechnicaNew HIV antibodies show potentialArs TechnicaMany researchers had given up on antibodies, which are used by the immune system to identify the signature proteins on the outside of invading cells, targeting them for destruction. The HIV virus…
|
Michael Neuberger: Unravelled the mysteries of human antibodies
Sydney Morning Herald His main scientific contributions lay in the field of antibodies – chemicals produced by blood cells called lymphocytes – which act as a natural defence against invaders such as bacteria and viruses. Lymphocytes turn out antibodies on demand that are … |
|
The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies …
PR Newswire (press release) EXTON, Pa., Oct. 31, 2013 /PRNewswire/ — BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar … |